FORM 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPF	₹OVAL
OMB Number:	3235-0362
Estimated averag	e burden
houre par raepane	20 10

	Check this box if no longer
	subject to Section 16. Form 4
	or Form 5 obligations may
	continue. See Instruction 1(b).
1	Form 3 Holdings Reported

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

1	Form 4 Transactions Reported Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the
	Investment Company Act of 1940

1. Name and Address of Reporting Person * 2. Issuer Name and Ticker or Trading Symbol Syros Pharmaceuticals, Inc. [SYRS]					ol	:	5. Relationship of Reporting Pers (Check all appli		ier	
(Last)	(First)	(Middle)	3. Statement for Is		ear Ended			Officer (give title below)	Other (specify	below)
C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300			(Month/Day/Year) 02/10/2017							
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Reporting (check applicable line)		
CAMBRIDGE, MA 02139								_X_ Form Filed by One Reporting PersonForm Filed by More than One Reporting Person		
(City)	(State)	(Zip)	Tabl	le I - Non-Deri	vative Sec	urities 2	Acqui	red, Disposed of, or Beneficially	y Owned	
1.Title of Security (Instr. 3)				(Instr. 8)	4. Securit (A) or Dis (Instr. 3, 4)	sposed of and 5) (A) or	of (D)	5. Amount of Securities Beneficially Owned at end of Issuer's Fiscal Year (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
Common Stock		02/09/2017		<u>J⁽¹⁾</u>	106,667	D	\$ 0	426,665	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 2270 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction	3A. Deemed	4.	5. Numl	ber 6	6. Date Exer	cisable	7. Titl	e and	8. Price of	9. Number	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transaction	of	a	and Expirati	on Date	Amou	nt of	Derivative	of	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code	Derivati	ive (Month/Day	/Year)	Under	lying	Security	Derivative	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Securiti	ies			Securi	ties	(Instr. 5)	Securities	Derivative	Ownership
	Derivative				Acquire	ed			(Instr.	3 and		Beneficially	Security:	(Instr. 4)
	Security				(A) or				4)			Owned at	Direct (D)	
					Dispose	ed						End of	or Indirect	
					of (D)							Issuer's	(I)	
					(Instr. 3	,						Fiscal Year	(Instr. 4)	
					4, and 5	5)						(Instr. 4)		
										Amount				
						_	<u> </u>	ъ						
							Date	Expiration Date	Title	Number				
						E	Exercisable	Date	(of				
					(A) (I	D)				Shares				

Reporting Owners

Reporting Owner Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Young Richard A C/O SYROS PHARMACEUTICALS, INC. 620 MEMORIAL DRIVE, SUITE 300 CAMBRIDGE, MA 02139	X					

Signatures

/s/ Kyle D. Kuvalanka, as attorney-in-fact	02/10/2017
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transfer made to former spouse pursuant to domestic relations order.

Note: File three copies of this Form, one of which must be manually signed. If space provided is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of informat number.	ion contained in this form are not required to respon	d unless the form displays a currently valid OMB